Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Parasit Vectors ; 7: 401, 2014 Aug 29.
Article in English | MEDLINE | ID: mdl-25174279

ABSTRACT

BACKGROUND: Cutaneous leishmaniasis (CL) is one of the common tropical protozoal diseases caused by various Leishmania species, and transmitted by the sand-fly vectors, Phlebotomus and Lutzomyia species. Herein, we report for the first time a case of CL that presented as large eczematous plaques occurring on the dorsi of both feet in a Libyan drug addicted, alcoholic patient with HIV infection. FINDINGS: A 34 year-old HIV-positive, alcoholic, drug addicted Libyan male presented to us with a history of a non-itchy skin lesions on the dorsi of both feet of 5-weeks duration. Systemic and topical antibiotics were given without improvement. Diagnosis of this patient was confirmed by observation of Leishmania amastigote bodies in stained slit-skin smear skin biopsy. After parenteral administration of sodium stiboglyconate (Pentostam) (20 mg/kg/day) for 28 days the lesions did not show any marked improvement. Concurrently, combination therapy of oral rifampicin (600 mg/day) and isoniazide (300 mg/day) was given for 8 weeks. Complete healing of lesions was achieved after this treatment and skin-slit smears turned negative. CONCLUSIONS: Localized cutaneous leishmaniasis should be remembered in deferential diagnosis of unresponsive contact dermatitis especially for HIV-positive patients in CL endemic areas.This patient was not responding to Pentostam therapy, which is not very common in Libya. Interestingly, combination of oral rifampicin (600 mg/day) and isoniazide (300 mg/day) can be a successful alternative therapy.


Subject(s)
HIV Infections/complications , Leishmaniasis, Cutaneous/complications , Leishmaniasis, Cutaneous/pathology , Adult , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Drug Therapy, Combination , Fatty Acid Synthesis Inhibitors/administration & dosage , Fatty Acid Synthesis Inhibitors/therapeutic use , Humans , Isoniazid/administration & dosage , Isoniazid/therapeutic use , Male , Nucleic Acid Synthesis Inhibitors/administration & dosage , Nucleic Acid Synthesis Inhibitors/therapeutic use , Rifampin/administration & dosage , Rifampin/therapeutic use , Skin/parasitology , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...